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Abstract: A thiol/disulfi de oxidoreductase component of the GSH system, 
glutaredoxin (Grx), is involved in the reduction of GSH-based mixed disul-
fi des and participates in a variety of cellular redox pathways. A single cy-
tosolic Grx (Grx1) was previously described in mammals. We now report 
identifi cation and characterization of a second mammalian Grx, designated 
Grx2. Grx2 exhibited 36% identity with Grx1 and had a disulfi de active cen-
ter containing the Cys-Ser-Tyr-Cys motif. Grx2 was encoded in the genomes 
of mammals and birds and expressed in a variety of cell types. The gene for 
human Grx2 consisted of four exons and three introns, spanned 10 kilobase 
pairs, and localized to chromosome 1q31.2–31.3. The coding sequence was 
present in all exons, with the fi rst exon encoding a mitochondrial signal pep-
tide. The mitochondrial leader sequence was also present in mouse and rat 
Grx2 sequences and was shown to direct either Grx2 or green fl uorescent pro-
tein to mitochondria. Alternative splicing forms of mammalian Grx2 mRNAs 
were identifi ed that differed in sequences upstream of exon 2. To functionally 
characterize the new protein, human and mouse Grx2 proteins were expressed 
in Escherichia coli, and the purifi ed proteins were shown to reduce mixed di-
sulfi des formed between GSH and S-sulfocysteine, hydroxyethyldisulfi de, or 
cystine. Grx1 and Grx2 were sensitive to inactivation by iodoacetamide and 
H2O2
 and exhibited similar pH dependence of catalytic activity. However, 
H2O2-inactivated Grx2 could only be reactivated with 5 mM GSH,
 whereas 
Grx1 could also be reactivated with dithiothreitol or thioredoxin/thioredoxin 
reductase. The Grx2 structural model suggested a common reaction mecha-
nism for this class of proteins. The data provide the fi rst example of a mito-
chondrial Grx and also indicate the occurrence of a second functional Grx in 
mammals. 
Abbreviations: The abbreviations used are: Trx, thioredoxin; Grx, glutare-
doxin; EST, expressed sequence tag; GFP, green fl uorescent protein; HEDS, 
hydroxyethyldisulfi de; DTT, dithiothreitol. 
INTRODUCTION
In animal cells, GSH and thioredoxin (Trx) systems are thought 
to be two major redox systems. They participate in a variety of cel-
lular functions, such as providing reducing equivalents for ribonucle-
otide reductase, antioxidant defense, control of cellular redox state, 
and the redox control of transcription and signal transduction (1–4). 
Trx and GSH systems exhibit partially overlapping functions but also 
display unique properties (2, 4). 
The Trx system, consisting of Trx, Trx reductase, and Trx perox-
idase (5, 6), was found in both cytosolic and mitochondrial fractions 
(7–9), and additional homologs of these proteins were also detected 
(6, 10, 11). The proteins of mitochondrial and cytosolic Trx systems 
were shown to be encoded by distinct genes. The components of the 
mitochondrial Trx system were identifi ed by the presence of signal 
peptides and by experiments that directly tested intracellular localiza-
tion of these proteins. 
The GSH system is composed of GSH, GSSG reductase, glu-
taredoxin (thiol/disulfi de oxidoreductase (Grx), also called thiol-
transferase), and GSH peroxidase (1, 3). The composition of Trx 
and GSH systems is similar in that Trx and Grx are thiol/disulfi de 
oxidoreductases characterized by the Trx fold; GSH peroxidase and 
Trx peroxidase are thiol-dependent peroxidases also containing the 
Trx fold; and Trx reductase and GSSG reductase are NADPH-de-
pendent FAD-containing homodimeric pyridine nucleotide disulfi de 
oxidoreductases. 
In contrast to the Trx system, the GSH system was only found 
and characterized in the cytosol. Moreover, single GSSG reductase 
and Grx genes were described in mammals, and only one GSH form 
exists in mammalian cells. However, GSSG reductase was shown to 
possess a mitochondrial signal peptide, allowing it to be directed to 
mitochondria (12). Likewise, GSH was detected in mitochondrial 
fractions (mitochondrial GSH accounts for ~10% of the cellular GSH 
pool), and two GSH peroxidases, GPx1 and GPx4, can also be tar-
geted to mitochondria (13, 14). Thus, Grx is the only component of 
the GSH system that was not found to reside in mitochondria. 
Grx is a small, 10–14-kDa GSH-dependent protein (1–4). Its 
function is to maintain reduced state of cysteines in cellular proteins. 
Like Trx, Grx contains the N-terminal redox center, the so-called 
CXXC motif (two cysteines separated by two other amino acid res-
idues). The Cys-Pro-Tyr-Cys version of this sequence is typically 
present in Grx. The two thiol groups in this motif are the source of 
reducing equivalents for substrate reduction. These residues form re-
versible disulfi de bond during catalysis and were shown to be the en-
zyme active site. Grx also contains conserved C-terminal sequences 
involved in GSH binding (15). 
It appears that the absence of Grx in mitochondria contrasts with 
the expected importance of this protein in providing reducing equiv-
alents for DNA synthesis and maintaining reduced status of thiols in 
proteins in this cellular compartment. In this report, we describe iden-
tifi cation and functional characterization of a mitochondrial Grx. 
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EXPERIMENTAL PROCEDURES
Expression Constructs — Expression constructs were generated using 
EST clones corresponding to mouse and human Grx2 mRNAs. The mouse 
Grx2 expression construct was generated by polymerase chain reaction am-
plifi cation using the mouse Grx2 cDNA as a template and primers contain-
ing NdeI (5’-GACACGTCATATGGGAAACAGCACATCGTC-3’) and XhoI 
(5’-CCACTCGAGATGTCTTTCCTCTTGTTTTTTTTTTAAATAACAC-
3’) sites. The human Grx2 sequence was amplifi ed by polymerase chain re-
action using a plasmid containing the human Grx2 insert as a template and 
primers containing NcoI (5’-ACAGCCATGGAGAGCAATACATCATC-3’) 
and XhoI (5’-TAACTCGAGCTGAAATTCTTTCCTCTTAC-3’) sites. The 
amplifi ed products and the pET21d(+) vector (Novagen) were digested with 
NcoI and XhoI, and the polymerase chain reaction fragments encompass-
ing the mouse or human Grx2 were ligated into the restricted pET21d(+) us-
ing T4 DNA ligase. Once subcloned, the amplifi ed regions were sequenced 
in their entirety. 
Purifi cation of Recombinant Proteins — Human and mouse Grx2 were 
expressed in Escherichia coli, and proteins were isolated as follows. Pro-
tein expression was induced with 1 mM isopropyl-1-thio-β-D-galactopyrano-
side in 200 ml of cell culture media. Cells were harvested by centrifugation 
at 10,000 × g for 10 min and resuspended in 8 ml of ice-cold 5 mM imidaz-
ole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9 (buffer A). After sonication, the ly-
sate was centrifuged at 18,000 × g for 20 min. The supernatant was applied 
onto a 5-ml His-bind column preequilibrated with buffer A. The column was 
washed with 30 ml of buffer A and, in addition, with 15 ml of 60 mM imid-
azole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9. Grx2 was eluted with 10 ml of 
1 M imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9. Human Grx1 was ex-
pressed in E. coli and purifi ed as described previously (16). 
Constructs with Green Fluorescent Protein (GFP) — For the N-Grx2-
GFP construct, the mouse Grx2 cDNA was amplifi ed with primers Grx2-
F1 (5’-CGAGCTCACCATGTCCTGGCGCCG-3’) and Grx2-R2 (5’-GTG-
GATCCCATGTCTTTCCTCTTGTT-3’) and cloned into the SacI/BamHI sites 
of pEGFP-N2 vector (CLONTECH). The Grx2-GFP construct was obtained 
by amplifi cation of the Grx2 cDNA with primers Grx2-F2 (5’-CGAGCT-
CACCATGGGAAACAGCACAT-3’) and Grx2-R2 and cloning the product 
into the SacI/BamHI sites of pEGFP-N2. The construct encoding the N-ter-
minal sequence of Grx2 (33 amino acids) fused to GFP (the N-GFP construct) 
was obtained by amplifi cation of the mouse cDNA with primers Grx2-F1 and 
Grx2-R1 (5’-TGGATCCCGAGCCCGCAGCT-3’) and cloning the product 
into the SacI/BamHI sites of pEGFP-N2. The GFP-N-Grx2 construct was ob-
tained by amplifi cation of the mouse Grx2 cDNA with Grx2-F1 and Grx2-
R2C (5’-TGGATCCATGTCTTTCCTCTTGTT-3’) and cloning the product 
into the SacI/BamHI sites of pEGFP-C3 vector (CLONTECH). All plasmids 
were transformed into E. coli strain NovaBlue (Novagen), and the plasmids 
were isolated using Plasmid Maxi Kit (Qiagen). 
Dual Fluorescence Confocal Microscopy — NIH-3T3 cells cultured in 
60-mm dishes were transfected with appropriate constructs using the cal-
cium phosphate method of transfection. Cells were transfected with 8.8 μg of 
plasmid as described (17) and incubated for 24 h in a CO2 incubator. A
 Mito-
Tracker (Molecular Probes, Inc., Eugene, OR) was used as a reference marker 
for mitochondria. The transfected cells were rinsed with serum-free Dulbec-
co’s modifi ed Eagle’s medium containing 10 mM HEPES and then incubated 
for 20 min at room temperature in the same medium containing MitoTracker 
at a 1:2000 dilution. The cells were washed twice with serum-free Dulbecco’s 
modifi ed Eagle’s medium-HEPES and were immediately used for image col-
lection. Double-labeled images of life cells were collected with water immer-
sion lens using a dual excitation/emission and dual channel mode on a Bio-
Rad MRC1024ES laser-scanning microscope. 
Grx Activity Assay — The standard assay for Grx2 activity was the pro-
cedure developed by Mieyal et al. (18, 19) and modifi ed by Raghavachari and 
Lou (20). Briefl y, the reaction mixture contained 0.2 mM NADPH, 0.5 mM 
GSH, 0.1 M potassium phosphate buffer (pH 7.4), 0.4 units of GSSG reduc-
tase, and an aliquot of purifi ed Grx2 in a total volume of 1 ml. The reaction 
was carried out at 30 °C following a 5-min preincubation with 2 mM syn-
thetic substrate, hydroxyethyldisulfi de (HEDS). The decrease in absorbance 
of NADPH at 340 nm was monitored for 5 min using Beckman DU 640 Spec-
trophotometer (Beckman, Fullerton, CA). To determine the Grx2 activity, the 
slope of the linear portion of the time course for 340-nm absorption loss in a 
control (Grx2-free) sample was subtracted from the slope of the samples con-
taining Grx2. One unit of Grx2 activity was defi ned as 1 μmol of NADPH ox-
idized per min under these standard assay conditions. 
Kinetic Studies and Temperature and pH Dependences of Catalytic Ac-
tivity — Temperature (20–45 °C) and pH (6.5–9.0) dependences of Grx2 ac-
tivities were determined using the standard Grx2 assay. Studies on substrate 
specifi cities utilized S-sulfocysteine and cystine in place of HEDS. Substrate 
concentrations were in the range of 0.0125–1.6 mM and assayed with 5 milli-
units of Grx2. The apparent Km and kcat values were calculated using the Line-
weaver-Burk plot. 
Effect of Iodoacetamide on Grx2 Activity — A 0.02-unit aliquot of re-
duced Grx2 was incubated with 30 μM iodoacetamide in 50 μl of 0.1 M po-
tassium phosphate buffer, pH 7.4, for 30 min prior to the Grx2 assay. 
Effect of H2O2 on Grx2 Activity — Purifi ed Grx2 was initially incubated 
with 5 mM DTT at room temperature for 30 min and fi ltered through PD-10 
column (Amersham Pharmacia Biotech) to remove unreacted DTT. An al-
iquot (0.02 units) of the resulting reduced Grx2 in 10 mM potassium phos-
phate buffer, pH 7.4, was preincubated with various concentrations of H2O2 
(0.125–1.5 mM) in a total volume of 6 μl for 5 min at 25 °C. Ten μl of cata-
lase (2 μg) was subsequently added, and the reaction mixture was incubated 
for additional 5 min at room temperature to degrade the remaining H2O2. The 
Grx2 activity was then determined using the standard Grx2 assay. To examine 
if H2O2-treated Grx2 could be reactivated
 by reducing agents, Grx2 (0.2 units) 
was incubated with 1 mM H2O2
 in 120 μl of 10 mM potassium phosphate 
buffer, pH 7.4, for 5 min at 25 °C. The reaction was stopped by adding 2 μg 
of catalase. The sample was then divided into six fractions, and each fraction 
was mixed with 0.1 mM phosphate buffer, pH 7.4, 5 mM DTT, 0.5 mM GSH, 
5 mM GSH, Trx/Trx reductase system, or Trx alone and incubated at 25 °C 
for 20 min. The fi nal volume of each reactivation reaction was 40 μl. Ten 
μl of each sample was used for the Grx2 assay. Concentrations of NADPH, 
E. coli Trx, and E. coli Trx reductase in the Trx/Trx reductase system were 
0.25 mM, 10 μM, and 0.8 μM, respectively. Trx/Trx reductase system without 
H2O2-inactivated
 Grx2 was used as a control. Human recombinant Grx1 was 
assayed in parallel with Grx2. 
Sequence Analyses — BLAST programs were used to search for homo-
logs of previously described glutaredoxins in EST and nonredundant data 
bases at the National Center for Biotechnology Information. These programs 
were also used to determine the structure of the human Grx2 gene and to 
identify alternative splicing forms of mammalian Grx2 mRNAs. Multiple se-
quence alignments were constructed using the ClustalW program. 
Molecular Modeling — Homology between Grx2 proteins and Grx from 
other sources was suffi cient to develop a molecular model of the core of the 
Grx2 structure. Mouse Grx2 tertiary structure was modeled using the SWISS-
MODEL program (21–23) and the following known three-dimensional struc-
tures as templates: the NMR solution structure of human Grx1 in the fully re-
duced form (1JHB) (24), crystal structure of pig Grx1 (1KTE) (25), and NMR 
structure of human mutant Grx1 complexed with GSH (1B4QA) (26). The mod-
eling was performed for sequences spanning residues 49–150 of mouse Grx2. 
Other Techniques — EST clones were obtained from Research Genet-
ics, and their nucleotide sequences were determined at the University of Ne-
braska–Lincoln DNA sequencing facility. SDS-polyacrylamide gel elec-
trophoresis was carried out using polyacrylamide gels, standards, and other 
electrophoretic reagents from Novex. 
RESULTS
Identifi cation and Sequence Analyses of Grx2 — Homology 
search analyses using known Grx sequences revealed a previously un-
characterized sequence that was represented by several mammalian 
ESTs. Multiple sequence alignments of human ESTs for this sequence 
identifi ed a cDNA that contained an open reading frame of 164 amino 
acid residues. Subsequent homology analyses revealed that this open 
reading frame was also encoded by mouse, rat, and swine ESTs, sug-
gesting that it was conserved among mammals and birds. 
Nucleotide sequences of representative human and mouse ESTs 
were experimentally verifi ed (Figure 1). The new human open read-
ing frame exhibited 36% identity to human Grx1 and was designated 
as Grx2. Multiple sequence alignments of human, mouse, and rat 
Grx2 with known Grx1 proteins (Figure 2A) indicated that Grx2 had 
a conserved disulfi de active center, the CXXC motif, typical of Grx 
and Trx proteins. In addition, sequences that were previously demon-
strated to be involved in GSH binding were conserved between Grx1 
and Grx2. Grx2 exhibited highest homology to Grx from plants and 
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fungi (e.g. 48% identity to Grx from a higher plant Vernicia fordii; 
accession number AF047694). It was also highly homologous to the 
N-terminal sequence of human thioredoxin reductase isozyme TGR 
that consists of a natural fusion of N-terminal Grx and C-terminal 
Trx reductase domains (39% identity, accession number AF171055). 
Two additional unpublished sequences for Grx2 recently appeared 
in GenBank™ (accession numbers NM016066 for CGI-133 protein 
and AF132495 for glutaredoxin 2). These sequences were in a good 
agreement with our human Grx2 sequence. 
Structure and Localization of the Human Grx2 Gene — Human 
Grx2 cDNA matched the internal sequences of human BAC clone 
RP11-101E13 (accession number AL136370), which allowed us to 
Figure 1. Amino acid and nucleotide sequences of mouse Grx2. The open reading frame is shown above the cDNA sequence. The active site Cys-Ser-Tyr-
Cys sequence is boxed. The termination signal is underlined. Numbers correspond to amino acid residues within mouse Grx2. The predicted mitochondrial sig-
nal peptide is underlined. 
Figure 2. Amino acid and nucleotide sequence analyses of mammalian Grx2 proteins. A, multiple sequence alignment of human, mouse, and rat Grx2, hu-
man Grx1, E. coli Grx1, and V. fordii (higher plant) Grx. Sequences of human and mouse Grx2 proteins were determined in the present study. The rat Grx2 se-
quence was compiled from 10 unique ESTs. Two conserved cysteines that are located in the N-terminal portion of the protein and that form a redox active center 
are shown by closed circles above the sequence. Residues identical in all six sequences are highlighted. The star above the sequences indicates a methionine resi-
due that is translated from the second in-frame ATG codon (see text for details). The line below the sequences indicates a conserved region that is involved in GSH 
binding. B, organization of the human Grx2 gene. Boxes indicate exons, and lines connecting boxes indicate introns. Open boxes indicate untranslated regions, and 
fi lled boxes indicate coding regions. The initiator and the second in-frame ATG codons are shown by arrows. Numbers under the boxes indicate nucleotides within 
the human genomic clone (accession number AL136370) derived from chromosome 1q31.2–31.3. 
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localize the Grx2 gene to human chromosome 1q31.2–31.3. Nucleo-
tide sequence identities with several other partial genomic sequences 
(e.g. BAC clones RP11-556C11 and RP11-239J11) also indicated the 
location of the human Grx2 gene on chromosome 1. Organization of 
the human Grx2 gene is shown in Figure 2B. The 10-kb gene con-
tained 4 exons and 3 introns with the coding regions present in exons 
1–4. The initiator ATG codon, in a moderately favorable Kozak con-
sensus sequence for initiation of translation (GCTATGC), was pres-
ent in the fi rst exon, while an additional in-frame ATG codon (in a 
more favorable Kozak sequence, GGAATGG) occupied nucleotide 
positions 2–4 within exon 2. 
Mitochondrial Signal Peptide — Examination of the human Grx2 
sequence with SignalP and PSORT programs indicated the presence 
of a predicted mitochondrial signal peptide (hydrophobic sequence 
with a high proportion of lysine or arginine residues that forms an 
amphiphilic α-helix). Mitochondrial leader sequences were also pres-
ent in mouse and rat Grx2 sequences. As often observed in mamma-
lian genes, the mitochondrial signal peptide was encoded by exon 
1, whereas sequences conserved within the Grx family of enzymes 
were encoded by downstream exons. 
Localization of Grx2 to Mitochondria — To test whether the fi rst 
exon of Grx2 encodes a signal peptide that directs the protein to mi-
tochondria, we expressed various fusion proteins of Grx2 and GFP, 
followed by the detection of GFP fl uorescence by confocal micros-
copy (Figure 3). When the N-terminal signal peptide of Grx2 was 
fused to the N terminus of GFP, the latter protein was detected in mi-
tochondria. Likewise, expression of a full-length Grx2 fused to the N 
terminus of GFP directed the fusion protein to mitochondria. How-
ever, GFP alone (data not shown) and GFP placed downstream of 
Grx2 that lacked the signal peptide were not directed to mitochondria 
and did not show any specifi c localization pattern. Thus, Grx2 has a 
functional mitochondrial signal peptide and should be considered a 
mitochondrial protein. Interestingly, when GFP was present upstream 
of the full-length Grx2 (last row in Figure 3), the fusion protein was 
signifi cantly enriched in nuclei. 
Alternative Splicing Forms — Examination of EST sequences 
for human, mouse, and rat Grx2 revealed alternative mRNA forms 
that differed in sequences upstream of exon 2. For example, a human 
cDNA sequence was detected (accession number AA421320) that 
contained sequences upstream of exon 1 on chromosome 1q31.2–
31.3, which replaced sequences corresponding to exon 1, whereas 
downstream sequences (exons 2–4) for both forms were identical. 
Alternative splicing forms of mouse (Figure 4A) and rat (Fig-
ure 4B) Grx2 mRNAs were also detected. These rodent forms either 
lacked sequences corresponding to a portion of exon 1 downstream 
of the translation initiation ATG codon or contained new sequences 
in place of sequences encoding mitochondrial signal peptides. In the 
rat, one alternative splicing form was represented by 12 ESTs, which 
is approximately half of all available rat Grx2 EST sequences. This 
alternative splicing form lacked 90 nucleotides within exon 1 that 
resulted in an in-frame stop signal between the initiation ATG and 
the second ATG codons (Figure 4B). Mouse EST sequences for 
Grx2 showed even more complex sequence variations. While se-
quences corresponding to exon 2 were identical in all mouse ESTs, 
we detected four distinct alternative sequences (accession numbers 
BE192757, AA466975, AA050108, and W61977) in place of se-
quences corresponding to exon 1 (Figure 4A). Overall, these data in-
dicated extensive sequence variations in 5’-sequences of mammalian 
Grx2 mRNAs and suggested alternative fi rst exon splicing as a mech-
anism to generate these mRNA forms.
 Expression of Grx2 mRNA — Grx2 was represented by 24 hu-
man ESTs derived from nine cDNA libraries, including nine fetal 
brain, four testes, two fetal kidney, and two colon ESTs as well as 
several individual sequences derived from prostate tumor, corneal 
stroma, HL60 (promyelocyte) cell line, kidney, and pancreatic adeno-
carcinoma. Mouse Grx2 was represented by 36 ESTs from 12 cDNA 
libraries. Like the human protein, it was highly represented by ESTs 
derived from testes (seven sequences), fetal (two sequences), and em-
bryonic (nine sequences) tissues. Mouse Grx2 was also represented 
by mammary gland, lymph node, kidney, thymus, placenta, myo-
tubes, proximal colon, and hypothalamus ESTs. The data suggested 
that Grx2 mRNA is expressed in a variety of tissues with possible in-
creased levels in testes and fetal and embryonic tissues. It should be 
noted that several cDNA libraries that contained Grx2 clones were 
normalized. This fact limits the assessment of absolute expression 
levels of Grx2 mRNA. 
Characterization of Recombinant Human and Mouse Grx2 — 
Human and mouse Grx2 were expressed in E. coli in the form of His-
tagged proteins. Recombinant proteins were isolated using a nickel 
affi nity column and analyzed by gel electrophoresis (Figure 5). To 
express mature human and mouse Grx2s (forms that lack mitochon-
drial leader peptides), constructs were developed in which translation 
was initiated from the second in-frame ATG codon that corresponded 
to nucleotides 2–4 within human exon 2. Examination of human and 
mouse recombinant proteins revealed little difference in their cata-
lytic activities (data not shown). 
Catalytic Properties of Grx2 — Catalytic properties of human 
Grx2 were determined in parallel with and compared with recombi-
nant human Grx1. The activity of Grx2 was limited to a narrow range 
of pH between 7.5 and 8.5, with the optimal pH of 8.0. This pH de-
pendence of Grx2 activity as well as temperature dependence (data 
not shown) were similar to those of Grx1 (17–19, 27). 
Figure 3. Expression of the GFP–Grx2 fusion proteins. Confocal images of 
NIH 3T3 cells expressing GFP-tagged Grx2 proteins are shown. A set of three 
images is shown for each construct. The left panels show green fl uorescence 
protein corresponding to transiently expressed fusion proteins; the center panels 
show fl uorescence of a mitochondrial marker, MitoTracker (Molecular Probes); 
and the right panels are obtained by merging the left and center panels. From 
top to bottom, the following are shown. N-Grx2-GFP, full-size Grx2 fused to 
the N terminus of GFP; Grx2-GFP, same construct in which the mitochondrial 
signal peptide was removed; N-GFP, signal peptide of Grx2 fused to the N ter-
minus of GFP; GFP-N-Grx2, full-length Grx2 fused to the C terminus of GFP. 
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Recombinant Grx2 catalyzed reduction of mixed disulfi des 
formed between GSH and HEDS, S-sulfocysteine, or L-cystine (Fig-
ure 6). The apparent Km values for HEDS, S-sulfocysteine,
 and L-
cystine were 1.68, 1.77, and 0.30 mM, respectively (Table I). The 
catalytic effi ciency (kcat/Km) of Grx2 was different
 for the three sub-
strates. Grx2 displayed the highest effi ciency with cystine, followed 
by HEDS and S-sulfocysteine with equal effi ciency (Table I). 
Sensitivity of Grx2 to Iodoacetamide and Hydrogen Peroxide — 
Grx2 activity was inhibited in the presence of the alkylating agent, 
iodoacetamide. Incubation of the protein with iodoacetamide for 
15 min resulted in 95% inhibition, suggesting that an active site SH 
group(s) was involved in the reaction catalyzed by Grx2. Grx2 was 
also partially inactivated when treated with H2O2. As
 shown in Fig-
ure 7, the activity loss was 20% in the presence of 0.1 mM and 40% 
in the presence of 0.5 mM H2O2 and remained at
 50–55% even af-
ter H2O2 was increased to 1.5 mM. The activity of
 Grx1 was also in-
hibited by H2O2 (Figure 7), as previously reported
 (28). Grx2 activity 
could be almost fully regenerated by treating the partially inactivated 
protein with 5 mM GSH; however, no protein reactivation was ob-
served in the presence of 5 mM DTT or the E. coli Trx/Trx reductase 
system (Table II). This observation contrasted with the fi nding that 
Grx1 could be reactivated by these reagents (data not shown). 
Molecular Modeling — Amino acid sequence similarity between 
Grx1 (for which several three-dimensional structures are available) 
and Grx2 was suffi cient to generate a molecular model of Grx2. We 
modeled mouse Grx2 structure using NMR structures of human Grx1 
and x-ray structure of pig Grx1 as templates (Figure 8). The predicted 
Grx2 structure revealed conservation of all major structural features 
found in mammalian Grx1. Specifi cally, Grx2 had a Trx fold that can 
be recognized by the presence of a characteristic β-sheet core sur-
rounded by α-helixes. The CXXC motif in Grx2 was located at the 
N-terminal end of a fi rst α-helix, which is another typical structural 
feature of Trx fold proteins. The close structural similarity between 
Grx1 and Grx2 could explain similarity in their catalytic properties. 
The model, however, was not suffi cient to explain differences in re-
activation properties between Grx1 and Grx2. 
Figure 4. Alternative splicing forms of rat and mouse Grx2. A, comparison of mouse Grx2 cDNA sequence (mitochondrial form) and alternative cDNA forms 
found by the analysis of mouse EST data base (accession numbers of EST sequences are indicated on the left). The second ATG codon (corresponds to ATG 
shown in Figure 2B, positions 2–4 within exon 2 of the human Grx2 gene) is shown in boldface type. The vertical line corresponds to the exon 1-exon 2 junction 
in the human Grx2 gene and separates alternative fi rst exon sequences from common downstream sequences. B, two alternative forms of the rat Grx2 cDNA. N-
terminal sequence of the mitochondrial form of rat Grx2 is shown at the top. This sequence is obtained by translating the nucleotide sequence shown below the 
amino acid sequence. Within this nucleotide sequence, lowercase letters indicate sequences that are lacking in the alternative form of rat Grx2. Translation of that 
cDNA form (shown below the nucleotide sequence) results in an in-frame stop signal followed by the second in-frame ATG codon. Two ATG codons that may 
potentially initiate translation are shown in boldface type and underlined. The corresponding Met residues are also shown in boldface type. 
Figure 5. Gel electrophoretic analysis of human and mouse recombinant 
Grx2. His-tagged human and mouse Grx2 were expressed in E. coli as de-
scribed under “Experimental Procedures.” The proteins were isolated using 
the nickel affi nity column and analyzed by SDS-polyacrylamide gel electro-
phoresis under reducing conditions. Coomassie Blue staining of the protein 
is shown. A, fractions containing human Grx2. B, fractions containing mouse 
Grx2. In both panels, lane 1 shows molecular weight standards (indicated by 
arrows on the left); lane 2 shows crude extracts of Grx2-overexpressing cells; 
lane 3 shows fl ow-through fraction obtained after crude extract was passed 
through the nickel affi nity column; and lane 4 shows Grx2 eluted from the 
nickel affi nity column. 
Figure 6. Substrate specifi city of human Grx2. Catalytic activities of hu-
man Grx2 were determined in the presence of 0–1.5 mM HEDS (diamonds), 
S-sulfocysteine (squares), or L-cystine (triangles) and expressed as mM 
NADP+ produced/min/μg of protein. 
Table I. Catalytic properties of Grx2 
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DISCUSSION
We described identifi cation and characterization of a novel mam-
malian mitochondrial glutaredoxin (thioltransferase), Grx2. The new 
protein exhibited only 36% sequence identity with the previously 
characterized mammalian cytosolic glutaredoxin, Grx1. However, it 
conserved the disulfi de active center CXXC sequence and a substrate 
binding motif and exhibited catalytic properties typical of previously 
characterized Grx proteins. 
To characterize Grx2, we analyzed catalytic properties of bac-
terially expressed and purifi ed mouse and human proteins in paral-
lel with Grx1. Substrate specifi city and substrate inhibition patterns 
were similar for two proteins. Likewise, Grx1 and Grx2 were both 
sensitive to inactivation by an alkylating agent, iodoacetamide, and 
an oxidant, hydrogen peroxide. However, the H2O2-inactivated
 Grx2 
could only be reactivated fully in the presence of high concentrations 
of GSH, while other strong reducing agents, such as DTT and Trx 
were not effective in Grx2 reactivation. This property of Grx2 distin-
guished this protein from Grx1, whose activity could be restored ef-
fectively by DTT or the Trx/Trx reductase system. 
The conserved sequences within mammalian Grx2 were pre-
ceded by a leader sequence indicative of a mitochondrial protein, and 
this signal was shown to direct either GFP or Grx2-GFP fusion pro-
tein to mitochondria. This fi nding that Grx2 resides in mitochondria 
is signifi cant in view of the previously established location of other 
components of the GSH system in this cellular compartment. Al-
though no mitochondrial Grx was previously reported in any eukary-
otic organism, our data suggest that Grx2 is a functional mitochon-
drial protein. 
The fi nding of a second Grx in mammals is similar to the fact 
that several Grx isoenzymes were previously described in bacteria, 
yeast, and plants. These proteins exhibit strong sequence homology, 
often have overlapping functions, and generally participate in the 
same or related metabolic pathways. However, recent evidence indi-
cates that Grx isozymes may also play unique roles in cellular redox 
regulation (2, 4, 29). 
The yeast Saccharomyces cerevisiae genome encodes two Grx 
isozymes containing the CXXC motif. Expression of both proteins 
is induced in response to oxidative, osmotic, and heat stress and in 
response to stationary phase growth and growth on nonfermentable 
carbon sources (30). In addition, yeast Grx1 and Grx2 are activated 
by the high osmolarity glycerol pathway and negatively regulated by 
the Ras-protein kinase A pathway. However, Grx1 is induced to sig-
nifi cantly higher levels compared with Grx2 following heat and os-
motic shock, whereas Grx2 is rapidly induced in response to reactive 
oxygen species and upon entry into stationary phase growth (30). 
In addition, the S. cerevisiae genome encodes three Grx iso-
zymes, which contain an active center motif with a single conserved 
Cys (29). The fi ve yeast Grx isozymes show a complex functional 
relationship, such as the synthetic lethality of either Grx5 and Grx2
Figure 7. Inactivation of human Grx1 and Grx2 
by hydrogen peroxide. Human Grx1 (squares) 
and Grx2 (diamonds) were treated with 0–1.6 mM 
hydrogen peroxide followed by analysis of their 
catalytic activities using the standard Grx assay. 
Enzyme activity is expressed as percentage of the 
initial activity. 
Table II. Oxidation of Grx2 by H2O2 and its reactivation by reductants 
Data are expressed as mean ± S.D. n = 3. 
Figure 8. Predicted three-dimensional structure of mouse Grx2. Molecu-
lar modeling of the Grx2 structure was performed with SWISS-MODEL pro-
gram. Sequence spanning residues 49–150 of mouse Grx2 was modeled. The 
active site cysteine residues (Cys70 and Cys73) are indicated. 
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mutations or inactivation of the Grx5 gene together with genes for 
Grx3 and Grx4. In addition, Grx5 plays a specifi c role in protection 
against oxidative and osmotic stresses (29). 
The E. coli genome encodes three functional Grx isozymes char-
acterized by common as well as unique functional properties (4). In 
contrast to E. coli and S. cerevisiae, where multiple Grx proteins oc-
cupy the same (cytosolic) compartment, the two mammalian Grx pro-
teins appear to reside in different compartments. Thus, the fi nding of 
similar catalytic profi les for these enzymes is not surprising. Expres-
sion patterns of Grx2 mRNA, which appears to be prevalent in fetal 
and embryonic tissues and in testes, may provide an additional clue 
to functional distinction between mammalian Grx1 and Grx2. 
In addition to mRNA forms encoding mitochondrial Grx2, we 
detected mRNA forms that were obtained by alternative splicing. 
Such forms were detected in the human, mouse, and rat sequences. 
Interestingly, some of the alternative forms contained in-frame stop 
signals. It is not clear how these forms could result in expression of 
functional proteins. One possibility is that the ATG codon that occu-
pies positions 2–4 within exon 2 in the human sequence and the cor-
responding ATG codons in the mouse and rat sequences could func-
tion as an alternative translation initiation site. This ATG is conserved 
in all mammalian Grx2 sequences, and we showed that it could ini-
tiate translation of human and mouse Grx2 proteins when these pro-
teins were expressed in E. coli. The use of this ATG codon to initiate 
protein synthesis may potentially result in a cytosolic form of Grx2. 
In addition, the fusion protein, in which GFP was upstream of Grx2, 
was enriched in nuclei, so we cannot exclude the nuclear location of 
some of the alternative splicing forms. 
This situation would be similar to expression of phospholipid 
hydroperoxide glutathione peroxidase, whose gene contains two in-
frame ATG codons. The use of the fi rst ATG yields a mitochondrial 
protein, whereas the second ATG also can initiate glutathione peroxi-
dase synthesis, resulting in a cytosolic enzyme. Moreover, the use of 
an alternative fi rst exon instead of the mitochondrial exon appears to 
direct the protein to the nucleus (31). 
The role of the GSH system in mitochondria is not fully under-
stood. Nevertheless, one may envision the importance of the GSH 
system in protecting this organelle from reactive oxygen species that 
are generated as by-products of metabolic processes. Grx2 may be 
expected to serve an important role in this protection by maintain-
ing reduced states of thiols in mitochondrial proteins and by reduc-
ing their glutathionylated cysteine residues with the concurrent ox-
idation of GSH to GSSG. This physiological function of Grx2 may 
also be extended to pathological and toxicological conditions that 
are characterized by elevated levels of reactive oxygen species gen-
erated in mitochondria and where the demand for the Grx function 
may be increased. 
Addendum — During the revision of this paper, a paper was pub-
lished online that also describes identifi cation and characterization of 
Grx2; see ref. #32. 
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